1. Noradrenaline stimulates gluconeogenesis through an (a-adrenoceptor in renal cortical tubule fragments from fed rats incubated with 5 mM-lactate. 2. The selective a1-adrenoreceptor agonist methoxamine stimulated gluconeogenesis, but the selective a2-adrenoceptor agonist clonidine was ineffective. 3. The selective a1-adrenoceptor antagonist thymoxamine blocked the stimulatory effects on gluconeogenesis of noradrenaline and of oxymetazoline (a synthetic a-agonist). The selective a2-adrenoceptor antagonist yohimbine was ineffective in this respect. 4. It is concluded that noradrenaline and oxymetazoline stimulate gluconeogenesis in rat kidney via an a1-rather than an a2-type of adrenoceptor.
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Gluconeogenesis in the rat renal cortex can be stimulated by catecholamines (Friedrichs & Schoner, 1973; Klahr et al., 1973 ; Kurokawa & Massry, 1973; Roobol & Alleyne, 1973; Guder & Rupprecht, 1975; Macdonald & Saggerson, 1977) . Studies with selective adrenergic agonists and antagonists have shown that this effect is mediated through an a-type of adrenoceptor (Guder & Rupprecht, 1975; Macdonald & Saggerson, 1977) . Recently, a considerable body of pharmacological evidence has accumulated consistent with the hypothesis that there may be more than one type of a-adrenoceptor. This distinction was first made between a-receptors on presynaptic sites and those on postsynaptic sites. Langer (1974) proposed that postsynaptic a-receptors be referred to as al and the presynaptic a-receptors, mediating feedback control by catecholamines of their own secretion from nerve endings, as a2. Subsequently this concept has been generalized to include the possibility that a2-receptors are also to be found in other than presynaptic sites; e.g. in platelets (Kafka et al., 1977; Wood et al., 1979; Hoffman et al., 1979) , uterus (Hoffman et al., 1979; Wood et al., 1979) , submandibular gland , parotid gland , melanocytes (Berthelsen & Pettinger, 1977) , guinea-pig kidney (Jarrott et al., 1979) and rat kidney cortex (U'Pritchard et al., 1978) . It is presumed therefore that the distinction between the al-and a2-receptors must be functional rather than anatomical, although the reason for this division of a-receptors is not understood at present.
The a-adrenoceptor agonist oxymetazoline stimulates gluconeogenesis in rat renal cortical tubules with considerable potency (Macdonald & Saggerson, 1977) . This agonist has been categorized as one that is more active at a2-receptors (Jones & Michell, 1978) . In many systems oxymetazoline would appear to be selective towards the a2-type of receptor (Starke et al., 1975b; Berthelsen & Pettinger, 1977; Drew, 1977 Drew, , 1978 Pichler & Kobinger, 1978; Jarrott et al., 1979) , but in some others the experimental evidence suggests selectivity towards a1-receptors (Struyker-Boudier et al., 1975; Drew, 1976; Doxey, 1979) . The actions of oxymetazoline in rat renal tubule fragments differ in several respects from those of adrenaline or noradrenaline. Firstly, oxymetazoline does not stimulate gluconeogenesis in the absence of extracellular Ca2+ or in the presence of low concentrations of Ca2+. The natural catecholamines, however, stimulate the process at all tested Ca2+ concentrations (Macdonald & Saggerson, 1977; P. Kessar & E. D. Saggerson, unpublished work) . Secondly, the stimulation of renal gluconeogenesis by oxymetazoline is less sensitive to abolition by ouabain than that brought about by noradrenaline (Saggerson & Carpenter, 1979) . Thirdly, oxymetazoline does not stimulate gluconeogenesis when succinate is the supporting substrate (Macdonald & Saggerson, 1977) whereas noradrenaline does (Guder & Rup-precht, 1975) . Fourthly, noradrenaline, but not oxymetazoline, can increase the efflux of 45Ca2+ from tubules prelabelled with this radionuclide (P. Kessar & E. D. Saggerson, unpublished results) . In addition, in rat liver, which appears to contain only a,-type adrenoceptors Hoffman et al., 1979) , oxymetazoline does not stimulate glycogenolysis or gluconeogenesis (Garrison & Borland, 1979) . It was therefore the purpose of this study to investigate the possibility that stimulation of renal gluconeogenesis by a-adrenoceptor agonists might involve a2-receptors or both al-and (t2-receptors, which are reported as being present in the proportions of 4:1 respectively in rat renal cortex (U'Pritchard et al., 1978) . A functional a2-receptor appears to operate in kidney to mediate catecholamine inhibition of renin secretion (Berthelsen & Pettinger, 1977) . This effect can also be demonstrated in the isolated rat kidney using the a2-adrenoceptor agonist clonidine (Vandongen & Greenwood, 1975) .
In the present study to investigate the type of a-adrenoceptor(s) involved in the control of gluconeogenesis we have used both the selective agonists methoxamine (a l-selective, Drew 1976 Drew , 1977 Drew , 1978 and clonidine (a2-selective, Starke et al., 1974; Drew, 1977 Drew, , 1978 and the selective blocking agents thymoxamine (a,-antagonist: Drew 1976 (a,-antagonist: Drew , 1978 and yohimbine (a2-antagonist: Starke et al., 1975a; Doxey et al., 1977; Drew, 1978) .
Materials and Methods Chemicals These were obtained and treated as described by Macdonald & Saggerson (1977 , 1978 (1977) .
Incubation techniques
All procedures were identical to those described by Macdonald & Saggerson (1977) . Incubations were for 1 h in 4 ml volumes containing KrebsRinger bicarbonate (Krebs & Henseleit, 1932) , 5mM-sodium L-lactate, 1.27 mM-Ca2+ and 10mg of fatty-acid-poor albumin/ml.
Analytical methods
After incubation, flask contents were deproteinized and glucose was measured as described previously (Macdonald & Saggerson 1977) . In all experiments the small amount of glucose initially present in non-incubated preparations was also determined and subtracted from experimental values. Tubule DNA was measured by the method of Burton (1956) .
Statistical methods
Analysis of data was performed on a paired basis and statistical significance determined by Student's t test.
Results and Discussion
Effects ofselective a-agonists Gluconeogenesis was stimulated by the selective al-agonist methoxamine. The maximum effect was increased gluconeogenesis by approx. 50% (Fig. 1) . Noradrenaline, (1lpM) which is the concentration of this agonist that gives maximum stimulation of the process (Guder & Rupprecht, 1975; Saggerson & Carpenter, 1979) , also stimulated gluconeogenesis by approx. 50%. On the other hand, gluconeogenesis was not significantly affected (.6%) by any of the tested concentrations (0.1nM-liuM) of the selective a2-agonist clonidine (Fig. 2) . That the tubules used in this experiment were normally responsive is shown by the 58% stimulation seen with luM-noradrenaline. These tubule preparations also responded to oxymetazoline (10 nM).
Effects ofselective a-adrenoceptor blocking agents The a-blocker thymoxamine is extremely selective for the postsynaptic a,-type of adrenoceptor (Drew, 1976 (Drew, , 1977 having little effect at a2-receptors. Figs. 3(a) and 3(b) show that 5,uM-thymoxamine caused considerable blockade of the actions of noradrenaline and oxymetazoline, displacing both dose-response curves to the right. Thymoxamine also caused a slight (non-significant) diminution in the maximum response to both noradrenaline and oxymetazoline. In the experiment shown in Fig. 3 (b) thymoxamine caused a small, but non-significant, decrease in the basal rate of gluconeogenesis but this effect was not always seen (e.g. Fig. 3a) . As found previously, (Macdonald & Saggerson, 1977) 130nM (Starke et al., 1975a; Marshall et al., 1977) .
Figs. 4(a) and 4(b) show that 0. I,uM-yohimbine slightly diminished the response to all tested concentrations of -noradrenaline and oxymetazoline. There was however little or no shift to the right of these dose-response curves, implying little or no competetive antagonism by this drug. Yohimbine had no effect upon basal gluconeogenesis in either experiment.
General discussion
The combination of the results obtained with the selective agonists and antagonists strongly suggests that (1-, but not 2-, adrenoceptors are involved in the (t-adrenergic stimulation of renal gluconeogenesis. The site of this process in the kidney is the proximal tubule (Guder & Schmidt, 1974) . It is possible therefore that this part of the nephron is devoid of (t2-adrenoceptors and the (t2-agonist binding sites reported by U' Pritchard el al. (1978) may be in other structures. Alternatively, the proximal tubular cells might contain (t2-receptors that do not couple to the effector system responsible for the stimulation of the gluconeogenic process.
In the system used here oxymetazoline would appear to act as an (xl-type of adrenoceptor agonist. This is contrary to many, but not all, assignments made for this drug on the basis of work with other systems (see introduction). 
